Target：Synphilin-1

Fields：Parkinson disease;Pathways of neurodegeneration - multiple diseases

Gene Name：SNCAIP

Protein Name：Synphilin-1

Human Gene Id：9627

Human Swiss Prot No：Q9Y6H5

Mouse Swiss Prot No：Q99ME3

Immunogen：The antiserum was produced against synthesized peptide derived from human Synphilin-1. AA range:797-846

Specificity：Synphilin-1 Polyclonal Antibody detects endogenous levels of Synphilin-1 protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:10000.. IF 1:50-200

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：SNCAIP;Synphilin-1;Sph1;Alpha-synuclein-interacting protein

Observed Band(KD)：100kD

Background： This gene encodes a protein containing several protein-protein interaction domains, including ankyrin-like repeats, a coiled-coil domain, and an ATP/GTP-binding motif. The encoded protein interacts with alpha-synuclein in neuronal tissue and may play a role in the formation of cytoplasmic inclusions and neurodegeneration. A mutation in this gene has been associated with Parkinson's disease. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015],

Function：disease:Defects in SNCAIP are a cause of Parkinson disease (PD) [MIM:168600]. PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.,miscellaneous:

Subcellular Location：Cytoplasm . Detected in cytoplasmic inclusion bodies, together with SNCA.

Expression：Detected in brain (at protein level). Widely expressed, with highest levels in brain, heart and placenta.